Back to search

Netherlands· NL-c02dca533804

LOQTORZI 240 mg concentraat voor oplossing voor infusie

A toripalimab product containing toripalimab, registered in Netherlands by Topalliance Biosciences Europe Limited. The same ATC class is registered in 12 of our 19 countries.

ATC L01FF13

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLOQTORZI 240 mg concentraat voor oplo…ATCL01FF13REGISTER NO.NL-c02dca533804PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Toripalimab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FF13 (toripalimab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose

Toripalimab · ATC L01FF13

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
TORIPALIMAB
Manufacturer
Topalliance Biosciences Europe Limited
Country
Netherlands (NL)
ATC code
L01FF13
ATC class
Toripalimab
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/24/1853

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/af6a8e94-e62e-436a-b17f-4e3a57f67568
GET /v1/drugs/af6a8e94-e62e-436a-b17f-4e3a57f67568?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/loqtorzi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Toripalimab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130789",
  "excipients": [
    "CITROENZUUR 1-WATER (E 330)",
    "MANNITOL (D-) (E 421)",
    "NATRIUMCHLORIDE",
    "POLYSORBAAT 80 (E 433)",
    "TRINATRIUMCITRAAT 2-WATER (E 331)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "TORIPALIMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/09/19",
  "procedure_number": "EMEA/H/C/006120",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/24/1853",
  "additional_monitoring": "Y"
}

See everything about toripalimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.